Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Breast Cancer - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.
The report delivers in-depth insights into over 250 companies and more than 300 pipeline drugs in the breast cancer landscape. It encompasses profiles of drugs at various stages, from clinical to nonclinical, and assesses therapeutics by product type, development stage, administration route, and molecule type. In addition, inactive pipeline products are highlighted to provide a comprehensive view of the field.
Breast cancer is one of the most common malignancies, greatly affecting women worldwide. Although detectable through routine screening, early-stage breast cancer often remains symptomless until further development. Symptoms may include breast lumps, changes in size or shape, unusual discharge, and persistent pain. Advances in understanding genetic mutations and molecular markers have significantly influenced prognosis and treatment strategies.
Diagnosing breast cancer involves imaging techniques such as mammography, ultrasound, or MRI, followed by biopsy for definitive analysis. Immunohistochemistry is used to evaluate hormone receptor and HER2 status, while CT or PET scans may assess metastatic spread. Staging using the TNM system aids in treatment planning and prognosis estimation. Treatment plans are highly personalized, consisting of combinations of surgery, radiotherapy, chemotherapy, hormonal, and targeted therapies. Promising immunotherapies are continually emerging.
The "Breast Cancer - Pipeline Insight, 2025" report illustrates the current setting and future growth opportunities in breast cancer treatment. Extensive details are provided, covering commercial and clinical assessments of pipeline products. Insightful data on drug mechanisms, clinical studies, NDA approvals, and product development activities are included, focusing on collaborations, mergers, acquisitions, and funding.
Report Highlights
- Collaborative efforts focusing on novel therapeutic approaches in breast cancer R&D.
- Detailed analysis of drugs in various clinical development stages.
- Insight into agreements, pharmacological actions, and industry news.
Emerging Drugs
- Vepdegestrant (ARV-471): Pfizer/Arvinas - Investigational protein degrader targeting estrogen receptors with Fast Track designation by the FDA.
- Utidelone: Biostar Pharma, Inc. - Approved in China for metastatic breast cancer, showing strong efficacy even in resistant cases.
- ARX788: Ambrx, Inc. - Anti-HER2 ADC in clinical trial stages, focusing on maximizing anti-tumor activity.
- TSL-1502: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. - Small molecule drug with promising preclinical results ready for Phase II trials.
- PF-07104091: Pfizer - CDK2 inhibitor with demonstrated preliminary efficacy, focusing on overcoming previous treatment resistance.
- XL092: Edgewood Oncology Inc. - Third-gen tyrosine kinase inhibitor in Phase I/II development for various advanced cancers, including breast cancer.
Therapeutic Assessment
- Overview of pipeline drugs, categorized by development stage and administration route.
- Analysis of different molecule types, product types, and their potentials.
Key Players in Breast Cancer
- Tanvex Biopharma
- Pfizer
- Biostar Pharma, Inc.
- Ambrx
- TSL Limited
- Edgewood Oncology Inc.
- and many more...
Key Questions Addressed
- How are emerging therapies influencing the breast cancer treatment landscape?
- What are the key partnerships and mergers shaping the industry?
- Which novel technologies are being developed to overcome existing therapy limitations?
Key Topics Covered:
Introduction
Executive Summary
Breast Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Breast Cancer - Analytical Perspective
Late Stage Products (Registration)
- Comparative Analysis
Vepdegestrant (ARV-471): Pfizer/ Arvinas
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
PF-07104091: Pfizer
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
XL092: Edgewood Oncology Inc.
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Breast Cancer Key Companies
Breast Cancer Key Products
Breast Cancer - Unmet Needs
Breast Cancer - Market Drivers and Barriers
Breast Cancer - Future Perspectives and Conclusion
Breast Cancer Analyst Views
Breast Cancer Key Companies
- Tanvex Biopharma
- Sichuan Kelun-Biotech Biopharmaceutical
- Shanghai Henlius Biotech
- Byondis
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Pfizer
- Jazz Pharmaceuticals
- Biostar Pharma, Inc.
- Chia Tai Tianqing Pharmaceutical Group
- InventisBio
- Coherent Biopharma
- Shanghai Jiaolian Drug Research and Development Co., Ltd
- Ambrx
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Tasly Pharmaceutical Group
- Convalife (Shanghai) Co., Ltd.
- Merck & Co
- AstraZeneca
- Aclaris Therapeutics
- Boehringer Ingelheim
- NovaOnco Therapeutics Co., Ltd.
- Verastem Oncology
- Ellipses Pharma
- Shenzhen Yangli Pharmaceutical Technology Co., Ltd
- TYK Medicine
- Ascendis Pharma
- ExpreS2ion Biotechnologies
- Mersana Therapeutics
- Exelixis
- Shenzhen Celconta Life Science
- Exelixis
- Beijing Wehand-Bio Pharmaceutical
- VM Oncology
- Hinova pharmaceuticals
- OS Therapies
- Syntab therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bivxky
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
